# PCORI Financial Profile

## Funding Capacity and Award History Analysis

---

## Cumulative Funding Summary

| Metric | Value |
|--------|-------|
| **Total Funding Awarded** | $5+ billion (since 2010) |
| **Total Projects Funded** | 2,621+ |
| **Average Funding per Project** | ~$1.9 million |
| **Years of Operation** | 14+ years (2010-present) |

### Historical Growth

| Period | Milestone |
|--------|-----------|
| 2010 | Congressional authorization |
| By 2024 (Aug-Dec) | $4.5 billion cumulative |
| By 2025 | $5.0+ billion cumulative |
| Annual Growth Rate | ~$500 million/year |

---

## Annual Funding Allocation (2025-2026)

### Total Available Funding (2025 Cycle)

| Program Area | Amount |
|--------------|--------|
| **Total 2025 Research Funding** | $500+ million |
| Phased Large Awards (PLACER) | $200 million |
| Broad Pragmatic Studies | $160 million |
| Implementation Projects | $23.5 million |
| Methods Development | $12 million |
| Science of Engagement | $36 million |
| Engagement Awards | $25 million |

### 2026 Funding Commitments

| Program | Cycle 1 2026 | Cycle 2 2026 |
|---------|--------------|--------------|
| Broad Pragmatic Studies | $120 million | TBD |
| PLACER | $120 million | TBD |
| Methods PFA | $12 million | $12 million |
| Engagement Awards | $25 million (FY2026 total) | Included |

---

## Award Categories and Amounts

### Research Awards

#### Broad Pragmatic Studies (BPS)

| Category | Direct Costs | Description |
|----------|--------------|-------------|
| **Category 1** | Up to $5 million | Standard pragmatic research projects |
| **Category 2** | $5 - $12 million | Large-scale studies requiring justification |
| **Category 3** | Up to $12 million | PCORnet-based national-scale studies |

- **Project Duration:** Up to 5 years
- **Total Available (Cycle 1 2026):** $120 million

#### Phased Large Awards (PLACER)

| Phase | Maximum | Duration |
|-------|---------|----------|
| **Feasibility Phase** | $2 million | 18 months |
| **Full-Scale Phase** | $20 million | Up to 5 years |
| **Total Maximum** | $22 million | ~6.5 years |

- **Minimum Expected Budget:** >$12 million direct costs
- **Total Available (Cycle 1 2026):** $120 million

#### Retrospective Observational Studies

| Metric | Value |
|--------|-------|
| **Maximum Direct Costs** | $2 million |
| **Maximum Duration** | 18 months |
| **Focus Areas** | Cancer, Pain, Substance Use, Maternal Health, IDD, Sensory Health, Metabolic/Endocrine, Mental Health, Rare Diseases |

#### Methods Research

| Metric | Value |
|--------|-------|
| **Maximum Direct Costs** | $750,000 |
| **Maximum Duration** | 3 years |
| **Total Available (per cycle)** | $12 million |
| **Priority Area 2026** | AI/ML Methods for CER |

### Engagement Awards

| Award Type | Maximum Amount | Duration |
|------------|----------------|----------|
| **Capacity Building** | $300,000 (total costs) | Up to 2 years |
| **Dissemination Initiative** | $300,000 (total costs) | Up to 2 years |
| **Convening Support** | Varies | Event-based |
| **Small Organizations** | $100,000 | Up to 2 years |

- **Total FY2026 Engagement Awards:** Up to $25 million

### Implementation Awards

| Metric | Value |
|--------|-------|
| **Total Available (Cycle 1 2026)** | Part of HSII allocation |
| **Eligibility** | Limited competition (prior awardees/HSII participants) |
| **Purpose** | Implement PCORI-funded research findings |

---

## Budget Policies and Requirements

### Indirect Cost Policy

| Policy Element | Rate/Requirement |
|----------------|-----------------|
| **Maximum Indirect Rate** | 40% of allowable direct costs |
| **Foreign Applicants** | Maximum 10% indirect |
| **Institutions without Federal Rate** | May request up to 10% |
| **Base Exclusions** | Equipment, patient care costs, subcontractor costs over $25,000 |

### Personnel Cost Limits

| Element | Limit |
|---------|-------|
| **Salary Cap** | $200,000 annual institutional base salary |
| **Fringe Benefits** | No cap on allowable rate |
| **Student Salaries** | Permitted |
| **Student Stipends** | Not allowable |

### Other Budget Considerations

| Category | Policy |
|----------|--------|
| **Equipment** | Items >$5,000 allowed with justification |
| **Travel** | Must benefit project; follow Uniform Guidance (2 CFR 200.474) |
| **DSMB Expenses** | Limited to 2% of total direct costs |
| **IRB Costs** | Allowable as direct cost with justification |
| **Work Visas** | Unallowable |
| **Patient Care Costs** | Requests >15% of research budget require strong justification |
| **Per-Participant Costs** | Studies >$40,000/participant are lower priority |

### Subcontract Policy

| Element | Requirement |
|---------|-------------|
| **First $25,000** | Eligible for prime applicant's indirect costs |
| **Above $25,000** | Excluded from prime's indirect cost base |
| **Fixed-Fee/Capitated** | Allowed with clear delineation and justification |

---

## Award History and Patterns

### Portfolio Distribution by Funding Type

| Funding Type | Number of Projects | Percentage |
|--------------|-------------------|------------|
| **Research** | 1,019 | 38.9% |
| **Engagement in Research** | 1,295 | 49.4% |
| **Dissemination & Implementation** | 154 | 5.9% |
| **Research Infrastructure** | 124 | 4.7% |
| **Other Evidence Products** | 29 | 1.1% |

### Project Status Distribution

| Status | Count | Percentage |
|--------|-------|------------|
| **Completed** | 1,922 | 73.3% |
| **Ongoing** | 534 | 20.4% |
| **In Peer Review** | 38 | 1.5% |
| **Other (pending, terminated)** | 127 | 4.8% |

### Awards by Research Area (Top 10)

| Health Focus Area | Projects | Est. Funding* |
|-------------------|----------|---------------|
| Mental/Behavioral Health | 414 | ~$785 million |
| Cardiovascular Diseases | 226 | ~$430 million |
| Cancer | 223 | ~$425 million |
| Respiratory Diseases | 171 | ~$325 million |
| Nutritional/Metabolic Disorders | 171 | ~$325 million |
| Neurological Disorders | 168 | ~$320 million |
| Infectious Diseases | 120 | ~$230 million |
| Bone/Joint Diseases | 110 | ~$210 million |
| Kidney/Urologic Diseases | 85 | ~$160 million |
| Blood Disorders | 75 | ~$145 million |

*Estimates based on average award size; actual amounts vary

### Geographic Distribution (Top 10 States)

| Rank | State | Projects |
|------|-------|----------|
| 1 | California | 290 |
| 2 | Massachusetts | 245 |
| 3 | Pennsylvania | 203 |
| 4 | Maryland | 147 |
| 5 | New York | 140+ |
| 6 | Texas | 120+ |
| 7 | North Carolina | 110+ |
| 8 | Illinois | 100+ |
| 9 | Colorado | 90+ |
| 10 | Florida | 85+ |

**Florida-Specific Notes:**
- Approximately 85+ funded projects
- University of Florida Health System: HSII Capacity Building participant
- Multiple implementation projects include Florida sites

---

## Recent Funding Announcements

### 2024 Funding Decisions

| Announcement | Funding Amount | Details |
|--------------|----------------|---------|
| March 2023 Awards | $123 million | 15 new research studies |
| Implementation Projects (2023) | $4 million | 2 new projects |
| August 2024 Awards | $165 million | New health research |
| Implementation Awards (2024) | $37 million | Evidence-based implementation |

### Committed Funding Focus Areas

| Priority Area | Commitment |
|---------------|------------|
| Pain Management Research | Up to $100 million |
| Mental/Behavioral Health | Up to $100 million |
| Obesity Treatment (2026) | Part of BPS SAE |
| IDD Care Delivery (2026) | Part of BPS SAE |
| AI/ML Methods | Part of Methods PFA |

---

## Health Equity and SDOH Investments

### Health Equity Research Priority

PCORI has designated **Achieve Health Equity** as a National Priority, reflected in:
- Dedicated funding for disparities research
- CHW/patient navigator intervention studies
- SDOH-focused funding announcements

### Relevant Funded Areas

| Focus Area | Examples |
|------------|----------|
| **Maternal Health Equity** | Community partnerships, SDOH integration |
| **CHW Interventions** | Program models, training, integration studies |
| **SDOH Screening** | Integration into clinical settings |
| **Care Navigation** | Patient navigation program comparisons |
| **IDD Health Access** | Systems-level access improvements |

### Cycle 3 2024 BPS - CHW/Navigator Studies

Explicitly welcomes studies examining:
- Different CHW program models
- Worker functions and training levels
- Certification approaches
- Implementation strategies
- Clinical team integration models

---

## Funding Success Indicators

### Application Statistics (Estimates)

| Metric | Estimate |
|--------|----------|
| **LOI Submission Rate** | 400-600 per cycle |
| **LOI to Full Application** | ~30-40% invited |
| **Full Application Funding Rate** | ~20-30% |
| **Overall Success Rate** | ~6-12% |

### Factors Associated with Success

1. **Strong Patient Engagement Plan** - Demonstrated meaningful engagement
2. **Clear Comparative Design** - Two or more interventions compared
3. **Patient-Centered Outcomes** - Outcomes important to patients
4. **Methodological Rigor** - Adherence to PCORI Methodology Standards
5. **Stakeholder Diversity** - Representative involvement
6. **Feasibility Evidence** - Preliminary data, team experience
7. **Health Equity Lens** - Disparities focus where applicable

---

## Strategic Financial Insights

### Optimal Award Targeting by Program Capability

| Organizational Capability | Recommended Program | Award Range |
|---------------------------|---------------------|-------------|
| Building engagement capacity | Engagement Awards | $100K-$300K |
| Pilot/feasibility research | Methods PFA | Up to $750K |
| Observational studies | Retrospective PFA | Up to $2M |
| Standard pragmatic trials | BPS Category 1 | Up to $5M |
| Large-scale trials | BPS Category 2 | $5M-$12M |
| Major multi-site trials | PLACER | $12M-$22M |

### Timing Considerations

| Factor | Consideration |
|--------|---------------|
| **Fiscal Year** | October 1 - September 30 |
| **Award Timing** | Typically December announcements |
| **Project Start** | Usually 3-4 months after award |
| **Multi-Year Funding** | Committed at award; no annual renewals |

---

## Financial Projections for FIU/NHELP/Thrive

### Potential Funding Pathway

| Phase | Program | Target Amount | Timeline |
|-------|---------|---------------|----------|
| Year 1 | Engagement Award (Capacity Building) | $250,000 | FY2026 |
| Year 2-3 | Methods PFA (AI/ML) | $500,000-$750,000 | FY2027 |
| Year 3-5 | BPS Category 1 or 2 | $5M-$12M | FY2028-2032 |

### Total Potential PCORI Investment

- **Conservative Estimate:** $5-6 million over 5-7 years
- **Optimistic Estimate:** $10-15 million over 5-7 years
- **Maximum Potential:** $20+ million with PLACER success

---

*Document compiled: February 2, 2026*
*Sources: PCORI Official Website, funding announcements, and portfolio data*
